|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu X, Shen SL and Wang YP: Current ststus
of comprehensive interventional therapy for advanced non-small cell
lung cancer. Zhonghua Fei Bu Ji Bing Za Zhi (Dian Zi Ban).
10:486–489. 2017.(In Chinese).
|
|
3
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
4
|
Catalano V, Turdo A, Di Franco S, Dieli F,
Todaro M and Stassi G: Tumor and its microenvironment: A
synergistic interplay. Semin Cancer Biol. 23:522–532. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mosser DM and Edwards JP: Exploring the
full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmieder A, Michel J, Schonhaar K, Goerdt
S and Schledzewski K: Differentiation and gene expression profile
of tumor-associated macrophages. Semin Cancer Biol. 22:289–297.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joshi N, Walter JM and Misharin AV:
Alveolar macrophages. Cell Immunol. 330:86–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Falini B, Flenghi L, Pileri S, Bigerna B,
Durkop H, Eitelbach F, Thiele J, Pacini R and Cavaliere A: PG-M1: A
new monoclonal antibody directed against a fixative-resistant
epitope on the macrophage-restricted form of the CD68 molecule. Am
J Pathol. 142:1359–1372. 1993.PubMed/NCBI
|
|
10
|
Gordon S: Alternative activation of
macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S,
Ma J, Ma L and You Z: The number and microlocalization of
tumor-associated immune cells are associated with patient's
survival time in non-small cell lung cancer. BMC Cancer.
10:2202010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Z, Maeda D, Yoshida M, Umakoshi M,
Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al:
The intratumoral distribution influences the prognostic impact of
CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Komohara Y, Jinushi M and Takeya M:
Clinical significance of macrophage heterogeneity in human
malignant tumors. Cancer Sci. 105:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sumitomo R, Hirai T, Fujita M, Murakami H,
Otake Y and Huang CL: M2 tumor-associated macrophages promote tumor
progression in non-small-cell lung cancer. Exp Ther Med.
18:4490–4498. 2019.PubMed/NCBI
|
|
15
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin CY, Siow TY, Lin MH, Hsu YH, Tung YY,
Jang T, Recht L and Chang C: Visualization of rodent brain tumor
angiogenesis and effects of antiangiogenic treatment using 3D
ΔR2-µMRA. Angiogenesis. 16:785–793. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sajib S, Zahra FT, Lionakis MS, German NA
and Mikelis CM: Mechanisms of angiogenesis in microbe-regulated
inflammatory and neoplastic conditions. Angiogenesis. 21:1–14.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao
HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic
cancer: Current research status and clinical implications.
Angiogenesis. 22:15–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weidner N, Folkman J, Pozza F, Bevilacqua
P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis:
A new significant and independent prognostic indicator in
early-stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y,
Kinoshita J, Miyazaki M and Abe T: Estimation of angiogenesis with
anti-CD105 immunostaining in the process of colorectal cancer
development. Surgery. 131:S109–S113. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu TH, Li YY, Wu TL, Chang JWC, Chou WC,
Hsieh LL, Chen JR and Yeh KY: Culture supernatants of different
colon cancer cell lines induce specific phenotype switching and
functional alteration of THP-1 cells. Cell Immunol. 290:107–115.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yeo EJ, Cassetta L, Qian BZ, Lewkowich I,
Li JF, Stefater JA III, Smith A, Wiechmann LS, Wang Y, Pollard JW
and Lang RA: Myeloid WNT7b mediates the angiogenic switch and
metastasis in breast cancer. Cancer Res. 74:2962–2973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohba K, Miyata Y, Kanda S, Koga S, Hayashi
T and Kanetake H: Expression of urokinase-type plasminogen
activator, urokinase-type plasminogen activator receptor and
plasminogen activator inhibitors in patients with renal cell
carcinoma: Correlation with tumor associated macrophage and
prognosis. J Urol. 174:461–465. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allavena P, Sica A, Solinas G, Porta C and
Mantovani A: The inflammatory micro-environment in tumor
progression: The role of tumor-associated macrophages. Crit Rev
Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou
J, Lu Y, Shi Y, Wang Z, Jiang L, et al: Anlotinib as a third-line
therapy in patients with refractory advanced non-small-cell lung
cancer: A multicentre, randomised phase II trial (ALTER0302). Br J
Cancer. 118:654–661. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Anagnostou VK and Brahmer JR: Cancer
immunotherapy: A future paradigm shift in the treatment of
non-small cell lung cancer. Clin Cancer Res. 21:976–984. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dancau AM, Simon R, Mirlacher M and Sauter
G: Tissue microarrays. Methods Mol Biol. 576:49–60. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WRR, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (Eighth) edition of the TNM Classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH,
Wang XZ, Zhao YW and Wei YQ: Prognostic significance of
tumor-associated macrophages in solid tumor: A meta-analysis of the
literature. PLoS One. 7:e509462012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Du ZY, Shi MH, Ji CH and Yu Y: Serum
pleiotrophin could be an early indicator for diagnosis and
prognosis of non-small cell lung cancer. Asian Pac J Cancer Prev.
16:1421–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Keskin S, Kutluk AC and Tas F: Prognostic
and predictive role of angiogenic markers in non- small cell lung
cancer. Asian Pac J Cancer Prev. 20:733–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang W, Ran R, Shao B and Li H:
Prognostic and clinicopathological value of PD-L1 expression in
primary breast cancer: A meta-analysis. Breast Cancer Res Treat.
178:17–33. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yagi T, Baba Y, Ishimoto T, Iwatsuki M,
Miyamoto Y, Yoshida N, Watanabe M and Baba H: PD-L1 Expression,
tumor-infiltrating lymphocytes, and clinical outcome in patients
with surgically resected esophageal cancer. Ann Surg. 269:471–478.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. New Eng J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Muz B, de la Puente P, Azab F and Azab AK:
The role of hypoxia in cancer progression, angiogenesis,
metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mazzieri R, Pucci F, Moi D, Zonari E,
Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L and
De Palma M: Targeting the ANG2/TIE2 axis inhibits tumor growth and
metastasis by impairing angiogenesis and disabling rebounds of
proangiogenic myeloid cells. Cancer Cell. 19:512–526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cooper WA, Tran T, Vilain RE, Madore J,
Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan
BC, et al: PD-L1 expression is a favorable prognostic factor in
early stage non-small cell carcinoma. Lung Cancer. 89:181–188.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schalper KA, Velcheti V, Carvajal D,
Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1
mRNA expression is associated with increased TILs and better
outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A,
Wu X, Cheng X, Xing X, Du H, et al: Level of circulating PD-L1
expression in patients with advanced gastric cancer and its
clinical implications. Chin J Cancer Res. 26:104–111.
2014.PubMed/NCBI
|
|
43
|
Droeser RA, Hirt C, Viehl CT, Frey DM,
Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A,
Rosso R, et al: Clinical impact of programmed cell death ligand 1
expression in colorectal cancer. Eur J Cancer. 49:2233–2242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sorensen SF, Zhou W, Dolled-Filhart M and
Georgsen J: 1328ppd-L1 expression and survival among advanced
non-small cell lung cancer (Nsclc) patients treated with
chemotherapy. Ann Oncol. 25 (Suppl 4):iv467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y,
Zhang Q, Zhang F, Liu H, Li T, et al: The clinicopathological and
prognostic significance of PD-L1 expression assessed by
immunohistochemistry in lung cancer: A meta-analysis of 50 studies
with 11,383 patients. Transl Lung Cancer Res. 8:429–449. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Keller MD, Neppl C, Irmak Y, Hall SR,
Schmid RA, Langer R and Berezowska S: Adverse prognostic value of
PD-L1 expression in primary resected pulmonary squamous cell
carcinomas and paired mediastinal lymph node metastases. Mod
Pathol. 31:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Igawa S, Sato Y, Ryuge S, Ichinoe M,
Katono K, Hiyoshi Y, Otani S, Nagashio R, Nakashima H, Katagiri M,
et al: Impact of PD-L1 expression in patients with surgically
resected non-small-cell lung cancer. Oncology. 92:283–290. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra1372012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mandarano M, Bellezza G, Belladonna ML,
Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V,
Ferri I, Bianconi F, et al: Assessment of TILs, IDO-1, and PD-L1 in
resected non-small cell lung cancer: An immunohistochemical study
with clinicopathological and prognostic implications. Virchows
Arch. 474:159–168. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sumitomo R, Hirai T, Fujita M, Murakami H,
Otake Y and Huang CL: PD-L1 expression on tumor-infiltrating immune
cells is highly associated with M2 TAM and aggressive malignant
potential in patients with resected non-small cell lung cancer.
Lung Cancer. 136:136–144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang
Y, Zhao J, Chen Y, Zhang T, Huang F, et al: Tumor cell-released
autophagosomes (TRAPs) promote immunosuppression through induction
of M2-like macrophages with increased expression of PD-L1. J
Immunother Cancer. 6:1512018. View Article : Google Scholar : PubMed/NCBI
|
